Logo image of BIAF

BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Fundamental Analysis

USA - NASDAQ:BIAF - US09076W3079 - Common Stock

1.46 USD
-0.01 (-0.68%)
Last: 11/20/2025, 2:00:03 PM
Fundamental Rating

1

Overall BIAF gets a fundamental rating of 1 out of 10. We evaluated BIAF against 533 industry peers in the Biotechnology industry. BIAF may be in some trouble as it scores bad on both profitability and health. BIAF does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BIAF had negative earnings in the past year.
In the past year BIAF has reported a negative cash flow from operations.
In the past 5 years BIAF always reported negative net income.
BIAF had a negative operating cash flow in each of the past 5 years.
BIAF Yearly Net Income VS EBIT VS OCF VS FCFBIAF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

BIAF has a worse Return On Assets (-246.03%) than 92.50% of its industry peers.
Industry RankSector Rank
ROA -246.03%
ROE N/A
ROIC N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIAF Yearly ROA, ROE, ROICBIAF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

BIAF's Gross Margin of 29.87% is fine compared to the rest of the industry. BIAF outperforms 73.36% of its industry peers.
BIAF does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIAF Yearly Profit, Operating, Gross MarginsBIAF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

BIAF does not have a ROIC to compare to the WACC, probably because it is not profitable.
BIAF has more shares outstanding than it did 1 year ago.
BIAF has a worse debt/assets ratio than last year.
BIAF Yearly Shares OutstandingBIAF Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
BIAF Yearly Total Debt VS Total AssetsBIAF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -22.82, we must say that BIAF is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -22.82, BIAF is doing worse than 85.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -22.82
ROIC/WACCN/A
WACC8.03%
BIAF Yearly LT Debt VS Equity VS FCFBIAF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

BIAF has a Current Ratio of 0.64. This is a bad value and indicates that BIAF is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.64, BIAF is doing worse than 91.18% of the companies in the same industry.
BIAF has a Quick Ratio of 0.64. This is a bad value and indicates that BIAF is not financially healthy enough and could expect problems in meeting its short term obligations.
BIAF's Quick ratio of 0.63 is on the low side compared to the rest of the industry. BIAF is outperformed by 90.99% of its industry peers.
Industry RankSector Rank
Current Ratio 0.64
Quick Ratio 0.63
BIAF Yearly Current Assets VS Current LiabilitesBIAF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

2

3. Growth

3.1 Past

BIAF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.81%, which is quite impressive.
Looking at the last year, BIAF shows a small growth in Revenue. The Revenue has grown by 4.97% in the last year.
EPS 1Y (TTM)22.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2584.21%
Revenue 1Y (TTM)4.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-47.07%

3.2 Future

BIAF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.26% yearly.
Based on estimates for the next years, BIAF will show a very negative growth in Revenue. The Revenue will decrease by -12.63% on average per year.
EPS Next Y41.46%
EPS Next 2Y29.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.4%
Revenue Next 2Y-12.63%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

BIAF Yearly Revenue VS EstimatesBIAF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2M 4M 6M 8M
BIAF Yearly EPS VS EstimatesBIAF Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIAF. In the last year negative earnings were reported.
Also next year BIAF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIAF Price Earnings VS Forward Price EarningsBIAF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIAF Per share dataBIAF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

BIAF's earnings are expected to grow with 29.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.26%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIAF!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOAFFINITY TECHNOLOGIES INC

NASDAQ:BIAF (11/20/2025, 2:00:03 PM)

1.46

-0.01 (-0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-30 2026-03-30
Inst Owners0.05%
Inst Owner Change2.28%
Ins Owners0.47%
Ins Owner Change0%
Market Cap6.57M
Revenue(TTM)7.68M
Net Income(TTM)-11.69M
Analysts43.33
Price TargetN/A
Short Float %2.54%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-32.35%
Min EPS beat(2)-66.67%
Max EPS beat(2)1.96%
EPS beat(4)1
Avg EPS beat(4)-29.08%
Min EPS beat(4)-66.67%
Max EPS beat(4)1.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.6%
Min Revenue beat(2)-17.38%
Max Revenue beat(2)-13.83%
Revenue beat(4)0
Avg Revenue beat(4)-12.73%
Min Revenue beat(4)-17.38%
Max Revenue beat(4)-9.27%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)0%
EPS NY rev (3m)-3500%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.86
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.27
EYN/A
EPS(NY)-8.26
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.71
OCFYN/A
SpS1.71
BVpS-0.47
TBVpS-0.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -246.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.87%
FCFM N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.62
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.85%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.64
Quick Ratio 0.63
Altman-Z -22.82
F-Score3
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)740.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2584.21%
EPS Next Y41.46%
EPS Next 2Y29.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-47.07%
Revenue Next Year-36.4%
Revenue Next 2Y-12.63%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29%
OCF growth 3YN/A
OCF growth 5YN/A

BIOAFFINITY TECHNOLOGIES INC / BIAF FAQ

Can you provide the ChartMill fundamental rating for BIOAFFINITY TECHNOLOGIES INC?

ChartMill assigns a fundamental rating of 1 / 10 to BIAF.


What is the valuation status of BIOAFFINITY TECHNOLOGIES INC (BIAF) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOAFFINITY TECHNOLOGIES INC (BIAF). This can be considered as Overvalued.


Can you provide the profitability details for BIOAFFINITY TECHNOLOGIES INC?

BIOAFFINITY TECHNOLOGIES INC (BIAF) has a profitability rating of 1 / 10.


How financially healthy is BIOAFFINITY TECHNOLOGIES INC?

The financial health rating of BIOAFFINITY TECHNOLOGIES INC (BIAF) is 0 / 10.